What is FloShield?
FloShield is at the forefront of developing advanced laparoscopic vision systems designed to improve surgical outcomes. Their flagship products, FloShield Air and FloShield Plus, utilize a unique Vortex Barrier Technology. This technology is engineered to maintain a clear field of vision for surgeons by effectively preventing condensation, debris, and smoke from obscuring laparoscope lenses during operations. By enabling intra-operative lens cleaning without the need to remove the scope, FloShield's solutions streamline surgical workflows, contributing to reduced procedure times and overall healthcare costs. The compatibility of their systems with a wide array of laparoscopes positions FloShield as a versatile provider for diverse surgical specialties.
How much funding has FloShield raised?
FloShield has raised a total of $15.5M across 3 funding rounds:
Private Equity
$1.4M
Private Equity
$2M
Series C
$12.1M
Private Equity (2008): $1.4M with participation from Canaan Partners, Radius Ventures, and Charter Life Sciences
Private Equity (2010): $2M led by Canaan Partners, Radius Ventures, and Charter Life Sciences
Series C (2015): $12.1M supported by Canaan Partners and Radius Ventures
Key Investors in FloShield
Canaan Partners
Canaan Partners is a venture capital firm with a focus on early-stage technology and healthcare companies, providing backing from seed to growth stages. Their investment in FloShield suggests a strategic interest in innovative medical devices and healthcare solutions.
Radius Ventures
Radius Ventures, a firm specializing in health and life sciences, has a history of investing in innovative companies aimed at transforming patient care. Their participation indicates confidence in FloShield's potential to advance medical technology and improve surgical practices.
Charter Life Sciences
Charter Life Sciences is a venture capital firm dedicated to providing initial funding for companies addressing significant unmet medical needs. Their involvement with FloShield highlights a commitment to supporting groundbreaking medical device innovations.
What's next for FloShield?
The substantial enterprise-level funding and recent strategic investment signal FloShield's transition into a scaling phase, likely aimed at expanding market penetration and further product development. This capital infusion is expected to fuel initiatives such as enhancing manufacturing capabilities, broadening sales and distribution networks, and potentially investing in research for next-generation surgical visualization tools. The company's focus on improving surgical efficiency and reducing costs aligns with current healthcare industry trends, positioning FloShield for sustained growth and a significant impact on minimally invasive surgery.
See full FloShield company page
